<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841304</url>
  </required_header>
  <id_info>
    <org_study_id>H-20069767</org_study_id>
    <nct_id>NCT04841304</nct_id>
  </id_info>
  <brief_title>Cardiac Arrhythmia in Patients With End-Stage Renal Disease</brief_title>
  <acronym>CADDY</acronym>
  <official_title>Cardiac Arrhythmia in Patients With End-Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the presence of cardiac arrhythmias in patients receiving hemodialysis&#xD;
      and the role of diabetes, hypoglycemia and parameters related to uremia and the dialysis&#xD;
      procedure.&#xD;
&#xD;
      The study is designed as a prospective cohort study with 18 months follow-up. 70 patients&#xD;
      receiving chronic hemodialysis will be recruited and equipped with implantable loop recorders&#xD;
      (ILR): 35 patients with diabetes and 35 patients without diabetes.&#xD;
&#xD;
      Data collection during the follow-up includes continuous monitoring of the heart rhythm by&#xD;
      the ILR for the entire follow-up period, continuous glucose monitoring for 10 days every&#xD;
      second month, and monthly collection of blood samples and dialytic parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically significant arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of one of the items in the combined endpoint of clinically significant arrhythmias defined as:&#xD;
Significant bradyarrhythmia (pause &gt; 3 seconds or ≥ 4 beats at rate &lt; 30 beats/min)&#xD;
Ventricular tachycardia (lasting ≥ 16 beats at rate ≥ 130 beats/min)&#xD;
Ventricular fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically significant arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of clinically significant arrhythmias (as defined above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of atrial fibrillation (lasting more than 2 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supraventricular tachycardia other than atrial fibrillation</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of supraventricular tachycardia other than atrial fibrillation (lasting ≥ 16 beats at rate ≥ 130 beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of hypoglycemic events &lt; 3.9 mmol/L (defined as sensor glucose below 3.9 mmol/L for ≥ 15 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range</measure>
    <time_frame>18 months</time_frame>
    <description>Time below range defined as percentage time with sensor glucose below 3.9 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias during hypoglycemia compared to euglycemia/hyperglycemia</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of arrhythmias during hypoglycemia compared with euglycemia/hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The temporal distribution of arrhythmias in relation to hypoglycemic events</measure>
    <time_frame>18 months</time_frame>
    <description>Arrhythmic events one hour prior to hypoglycemia, during hypoglycemia and one hour post hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in arrhythmias between patients with insulin-treated diabetes and patients without diabetes</measure>
    <time_frame>18 months</time_frame>
    <description>Difference in arrhythmias between patients with insulin-treated diabetes and patients without diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between urinary creatinine clearance and risk of arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between urinary creatinine clearance at baseline and risk of arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between macrovascular complications and risk of arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between macrovascular complications (myocardial infarction, stroke, peripheral vascular disease) at baseline and risk of arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between ultrafiltration rate and risk of arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between ultrafiltration rate during a dialysis session and risk of arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between a decline in systolic blood pressure during dialysis and risk of arrythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between a decline in systolic blood pressure ≥20 mmHg during a dialysis session and risk of arrythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between pre-dialysis plasma electrolyte concentrations and risk of arrhythmias</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between pre-dialysis plasma electrolyte concentrations and risk of arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The temporal distribution of arrhythmias in relation to dialysis sessions</measure>
    <time_frame>18 months</time_frame>
    <description>The temporal distribution of arrhythmic events in relation to dialysis sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden cardiac death</measure>
    <time_frame>18 months</time_frame>
    <description>Sudden cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>18 months</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>An arrhythmia leading to an intervention</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of any arrhythmia leading to an intervention defined as implantation of a cardiac implantable electronic device or medical intervention (any change in prescribed medication)</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of adverse events, including procedure related adverse events</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>End Stage Renal Disease on Dialysis</condition>
  <condition>Cardiac Arrhythmia</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Patients receiving hemodialysis with diabetes</arm_group_label>
    <description>Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving glucose-lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving hemodialysis without diabetes</arm_group_label>
    <description>Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, and HbA1c &lt; 48 mmol/mol at inclusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Loop recorder (Reveal LINQ, Medtronic)</intervention_name>
    <description>Implantation of a loop-recorder</description>
    <arm_group_label>Patients receiving hemodialysis with diabetes</arm_group_label>
    <arm_group_label>Patients receiving hemodialysis without diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Measurement (G6, Dexcom)</intervention_name>
    <description>Monitoring with a continuous glucose monitor</description>
    <arm_group_label>Patients receiving hemodialysis with diabetes</arm_group_label>
    <arm_group_label>Patients receiving hemodialysis without diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        70 subjects receiving chronic hemodialysis therapy:&#xD;
&#xD;
          -  35 subjects with diabetes&#xD;
&#xD;
          -  35 subjects without diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with diabetes:&#xD;
&#xD;
          -  Type 1 diabetes or Type 2 diabetes diagnosed according to the criteria of the World&#xD;
             Health Organization&#xD;
&#xD;
          -  Ongoing glucose-lowering treatment&#xD;
&#xD;
          -  Receiving chronic hemodialysis for more than 3 months&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Patients without diabetes:&#xD;
&#xD;
          -  HbA1c &lt; 48 mmol/mol&#xD;
&#xD;
          -  Receiving chronic hemodialysis for more than 3 months&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          -  Already treated with pacemaker or implantable cardioverter defibrillator (ICD)&#xD;
&#xD;
          -  Permanent (chronic) atrial fibrillation&#xD;
&#xD;
          -  Previously diagnosed sustained (&gt; 30 seconds) ventricular tachycardia (more than 200&#xD;
             bpm) or ventricular fibrillation (note that ventricular premature beats is not&#xD;
             considered an exclusion), or known cardiac ion-channel diseases (such as Long QT&#xD;
             syndrome and Brugada syndrome)&#xD;
&#xD;
          -  Previously complications in relation to wearing a CGM sensor, e.g. allergic reaction&#xD;
&#xD;
          -  Inability to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dea H Kofod, MD</last_name>
    <phone>004527143834</phone>
    <email>dea.haagensen.kofod.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dea H Kofod, MD</last_name>
      <phone>+4527143834</phone>
      <email>dea.haagensen.kofod.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lindhardt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Holbæk Sygehus</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Lindhardt</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Bo Feldt-Rasmussen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

